What is PhotonPharma?
PhotonPharma Inc. is a biotechnology firm dedicated to pioneering novel treatments for solid tumor cancers. Their lead product, Innocell, is an autologous vaccine engineered to extend disease progression for patients. The company is actively advancing Innocell through a Phase 1 clinical trial, evaluating its safety and immunogenicity in individuals with recurrent epithelial ovarian cancer. PhotonPharma's strategic focus is on enhancing therapeutic outcomes for patients aged 18 and above, complementing established treatments like chemotherapy, immunotherapy, and surgical interventions.
How much funding has PhotonPharma raised?
PhotonPharma has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2024): $2.5M, investors not publicly disclosed
What's next for PhotonPharma?
The recent major strategic investment positions PhotonPharma for accelerated development and potential market entry. This financing is expected to fuel the advancement of their Innocell vaccine through critical clinical trial phases, particularly in ovarian cancer. The company's trajectory suggests a move towards scaling operations and potentially seeking further rounds of financing to support broader clinical studies and eventual commercialization, solidifying its role in the oncology landscape.
See full PhotonPharma company page
